Long-Term Treatment-Free Survival After Multimodal Therapy in a Patient with Stage IV Lung Adenocarcinoma

Hatsuyo Takaoka, Hideki Terai, Katsura Emoto, Lisa Shigematsu, Fumimaro Ito, Ayaka Saito, Masahiko Okada, Keiko Ohgino, Shinnosuke Ikemura, Hiroyuki Yasuda, Ichiro Nakachi, Ichiro Kawada, Koichi Fukunaga, Kenzo Soejima

Research output: Contribution to journalArticlepeer-review


We report the first case of a patient with non-small cell lung cancer (NSCLC) with malignant pleural effusion (MPE) who achieved disease-and treatment-free survival for nearly 10 years. A 50-year-old man was diagnosed with NSCLC with MPE and underwent chemotherapy and salvage thoracic surgery. The patient received chemotherapy with cisplatin, pemetrexed, and bevacizumab, and a partial response was achieved. After informed consent was obtained from the patient, right middle lobectomy was performed to achieve local tumor control. Postoperative adjuvant chemotherapy with pemetrexed and bevacizumab was discontinued after almost 1 year of chemotherapy due to side effects such as diarrhea and muscle weakness. The patient has survived without recurrence of lung cancer for more than 11 years after being diagnosed and nearly 10 years after discontinuing chemotherapy.

Original languageEnglish
Pages (from-to)981-989
Number of pages9
JournalOncoTargets and Therapy
Publication statusPublished - 2022


  • bevacizumab
  • cure
  • malignant pleural effusion
  • pemetrexed
  • salvage surgery

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Long-Term Treatment-Free Survival After Multimodal Therapy in a Patient with Stage IV Lung Adenocarcinoma'. Together they form a unique fingerprint.

Cite this